Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
GHRP-2
One of the original growth-hormone secretagogue peptides — real pharmacology, no approved physique indication, and formal FDA compounding safety concerns.
GHRP-6
The older sibling of GHRP-2, with historical human pharmacology but no approved indication and a notable appetite-stimulating effect.
How far human research has progressed
GHRP-2
Historical human pharmacology studies; no approved therapeutic programmeGHRP-6
Historical human pharmacology onlyClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
GHRP-2
Not separately assessed; see the full profile.GHRP-6
Not separately assessed; see the full profile.Human research context
GHRP-2
Historical human pharmacology studies; no approved therapeutic programmeGHRP-6
Historical human pharmacology onlyHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
GHRP-2
GHRP-6
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
GHRP-2
GHRP-6
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
GHRP-2
GHRP-6
Regulatory status (legal position, not proof it works)
GHRP-2
Check jurisdiction-specific details in the profile.
Not an FDA-approved medicine. The FDA's compounding safety material flags GHRP-2 across injectable and nasal routes, citing immunogenicity and impurity concerns and published serious adverse event case reports.
GHRP-6
Check jurisdiction-specific details in the profile.
Not an approved medicine in any major region; sold in the research market for physique and anti-ageing claims that have never been trialled.
Common claims
GHRP-2
- · Raises growth hormone for muscle gain and fat loss
- · Anti-ageing GH restoration
GHRP-6
- · Builds muscle and reduces fat via growth hormone
- · Anti-ageing benefit
How settled our evidence rating is
GHRP-2
GHRP-6
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
GHRP-2
Sustained IGF-1 elevation is a theoretical proliferation concern shared across the GH axis. No human cancer outcome data exist for GHRP-2 itself.GHRP-6
Indirect IGF-1 elevation carries the same theoretical proliferation concern as the rest of the GH axis. No human cancer outcome data exist.What this adds up to, in plain English
GHRP-2
The interesting work is in animals and lab studies. Treating it as an established human treatment is not supported by evidence.GHRP-6
The interesting work is in animals and lab studies. Treating it as an established human treatment is not supported by evidence.A comparison is not a recommendation